On March 3, 2026, the FDA announced it had issued 30 warning letters to telehealth companies over allegedly false or misleading compounded GLP-1 marketing claims
Prescribing of AOM tirzepatide (brand name Zepbound) was observed in the first month of availability in pharmacies, December 2023
Qu papel juegan los anlogos del GLP-1/GIP y glucagn
During a consultation, your provider will help decide the best course of action, considering health, preferences, and insurance coverage
After a reviewing the evidence from non-clinical studies, clinical trials, and data from post-marketing surveillance, The European Medicines Agency (EMA) committee concluded that NAION is associated with use of semaglutide (the active ingredient in Ozempic and Wegovy)